- Home
- DNTH vs CSWC Comparison
DNTH vs CSWC Comparison
Compare DNTH & CSWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- CSWC
- Stock Information
- Founded
- DNTH 2015
- CSWC 1961
- Country
- DNTH United States
- CSWC United States
- Employees
- DNTH N/A
- CSWC N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- CSWC Textiles
- Sector
- DNTH Health Care
- CSWC Consumer Discretionary
- Exchange
- DNTH Nasdaq
- CSWC Nasdaq
- Market Cap
- DNTH 1.4B
- CSWC 1.1B
- IPO Year
- DNTH N/A
- CSWC N/A
- Fundamental
- Price
- DNTH $33.73
- CSWC $20.57
- Analyst Decision
- DNTH Strong Buy
- CSWC Buy
- Analyst Count
- DNTH 11
- CSWC 5
- Target Price
- DNTH $65.22
- CSWC $23.50
- AVG Volume (30 Days)
- DNTH 503.3K
- CSWC 638.5K
- Earning Date
- DNTH 11-05-2025
- CSWC 11-03-2025
- Dividend Yield
- DNTH N/A
- CSWC 12.40%
- EPS Growth
- DNTH N/A
- CSWC N/A
- EPS
- DNTH N/A
- CSWC 1.62
- Revenue
- DNTH $4,854,000.00
- CSWC $217,271,000.00
- Revenue This Year
- DNTH N/A
- CSWC $14.60
- Revenue Next Year
- DNTH N/A
- CSWC $10.75
- P/E Ratio
- DNTH N/A
- CSWC $12.68
- Revenue Growth
- DNTH 17.87
- CSWC 11.39
- 52 Week Low
- DNTH $13.37
- CSWC $17.46
- 52 Week High
- DNTH $40.16
- CSWC $23.86
- Technical
- Relative Strength Index (RSI)
- DNTH 47.36
- CSWC 46.55
- Support Level
- DNTH $32.28
- CSWC $19.91
- Resistance Level
- DNTH $35.40
- CSWC $21.00
- Average True Range (ATR)
- DNTH 1.62
- CSWC 0.39
- MACD
- DNTH -0.20
- CSWC 0.06
- Stochastic Oscillator
- DNTH 27.78
- CSWC 60.55
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About CSWC Capital Southwest Corporation
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.